Remove 2019 Remove Download Remove Epilepsy Remove Safety
article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

NICE guideline [NG144] Published date: November 2019. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. 1.4 Severe treatment-resistant epilepsy. NICE has made research recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy. Chronic pain.

article thumbnail

CBD Market Report

Project CBD

Sales appear to have peaked in 2019, when natural channel consumers spent more than $90.7 Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Epilepsy Behav.

CBD 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Conclusions.

article thumbnail

Medical Cannabis Company Sunshine Coast Tikun Oceana, formerly known as Medifarm Calls In The Administrators

Cannabis Law Report

The schedule eight pharmaceutical medicine has gained federal approval to treat conditions including cancer-related pain, nausea and vomiting, multiple sclerosis and epilepsy, and for use in palliative care. “Not just the perimeter security, but also the safety and security onsite is paramount.” The Hon Greg Hunt MP.